SCHEMBL430341

SCHEMBL430341

NC1(CC(=O)O)CCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL289131 0.95 CYP1A2 (0.52)
Hydrochloric Acid SCHEMBL3705397 0.92 CYP1A2 (0.50)
SCHEMBL20198601 0.92 TSHR (0.56)
SCHEMBL20104809 0.92 TSHR (0.56)
SCHEMBL498155 0.92 TSHR (0.56)
Hydrochloric Acid SCHEMBL7609840 0.90 TSHR (0.54)
SCHEMBL4115624 0.89
Hydrochloric Acid SCHEMBL16666607 0.86
Sulfuric Acid SCHEMBL4208350 0.84 CYP1A2 (0.48)
Trifluoroacetic Acid SCHEMBL22342626 0.81 USP2 (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103880768-B A kind of chemical synthesis process of 3-cyclobutyl morpholine NANTONG UNIVERSITY (CN) 2016-04-13 CN claimed
EP-2881384-B1 PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND TAISHO PHARMACEUTICAL CO LTD (JP) 2018-05-30 EP disclosed
EP-2834220-B1 4-HYDROXY-ISOQUINOLINE COMPOUNDS AS HIF HYDROXYLASE INHIBITORS FIBROGEN INC (US) 2016-11-09 EP disclosed
US-9422240-B2 Partially saturated nitrogen-containing heterocyclic compound TAISHO PHARMACEUTICAL CO., LTD (JP) 2016-08-23 US disclosed
US-9409892-B2 4-hydroxy-isoquinoline compounds as HIF hydroxylase inhibitors FIBROGEN, INC. (US) 2016-08-09 US disclosed
CN-103880768-B A kind of chemical synthesis process of 3-cyclobutyl morpholine NANTONG UNIVERSITY (CN) 2016-04-13 CN disclosed
CN-103880768-B A kind of chemical synthesis process of 3-cyclobutyl morpholine NANTONG UNIVERSITY (CN) 2016-04-13 CN disclosed
US-20150175541-A1 PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND TAISHO PHARMACEUTICAL CO., LTD (JP) 2015-06-25 US disclosed
EP-2881384-A1 PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND Taisho Pharmaceutical Co., Ltd. (JP) 2015-06-10 EP disclosed
CN-104470899-A 4-hydroxy-isoquinoline compounds as HIF hydroxylase inhibitors FIBROGEN INC 2015-03-25 CN disclosed
CN-103880768-A Chemical synthesis method of 3-cyclobutylmorpholine UNIV NANTONG 2014-06-25 CN disclosed
WO-2013134660-A1 4 -HYDROXY- ISOQUINOLINE COMPOUNDS AS HIF HYDROXYLASE INHIBITORS FIBROGEN, INC. (US) 2013-09-12 WO disclosed
US-8501782-B2 Piperidinyl derivatives as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2013-08-06 US disclosed
US-20120022030-A1 Tetracyclic Lactame Derivatives NOVARTIS AG 2012-01-26 US disclosed
US-7838674-B2 2-(1-amino-cyclobutylmethyl)-8-(4-methoxy-phenyl)-4,5-dihydro-1 H-1,7,9-triazacyclopenta[a]naph-thalene-3-carboxylic acid lactame; useful especially as inhibitors of mitogen-activated protein kinase-activated protein kinase-2 (MK2 or MAPKAP kinase-2 NOVARTIS AG (CH) 2010-11-23 US disclosed
US-20100204274-A1 PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY 2010-08-12 US disclosed
US-20100204274-A1 PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY BRISTOL-MYERS SQUIBB COMPANY 2010-08-12 US disclosed
EP-2178874-A1 HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS Novartis Ag (CH) 2010-04-28 EP disclosed
US-20090098218-A1 Tetracyclic Lactame Derivatives NOVARTIS AG 2009-04-16 US disclosed
WO-2009010488-A1 HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS NOVARTIS AG (CH) 2009-01-22 WO disclosed